Aclaris Therapeutics IncNASDAQ:ACRS
- LAST PRICE1.1900
- TODAY'S CHANGE (%)0.0100 (0.8475%)
- Bid / Lots1.1400/ 1
- Ask / Lots1.2200/ 30
- Open / Previous Close1.2000 / 1.1800
- Day Range
- 52 Week Range
- Volume446,399
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACRS |
|---|---|---|
| 09:32 ET | 27181 | 1.19 |
| 09:34 ET | 3400 | 1.1902 |
| 09:38 ET | 14809 | 1.17 |
| 09:41 ET | 247 | 1.175 |
| 09:45 ET | 270 | 1.175 |
| 09:48 ET | 4929 | 1.185 |
| 09:50 ET | 15422 | 1.1895 |
| 09:52 ET | 7013 | 1.18 |
| 09:56 ET | 1300 | 1.18 |
| 09:59 ET | 600 | 1.18 |
| 10:01 ET | 1000 | 1.17 |
| 10:03 ET | 800 | 1.17 |
| 10:06 ET | 200 | 1.175 |
| 10:08 ET | 400 | 1.175 |
| 10:10 ET | 700 | 1.17 |
| 10:15 ET | 100 | 1.175 |
| 10:19 ET | 100 | 1.175 |
| 10:24 ET | 200 | 1.175 |
| 10:28 ET | 3318 | 1.185 |
| 10:30 ET | 800 | 1.1805 |
| 10:32 ET | 665 | 1.185 |
| 10:37 ET | 200 | 1.182 |
| 10:42 ET | 100 | 1.19 |
| 10:44 ET | 849 | 1.185 |
| 10:50 ET | 100 | 1.185 |
| 10:51 ET | 100 | 1.185 |
| 10:53 ET | 100 | 1.185 |
| 10:55 ET | 501 | 1.185 |
| 11:00 ET | 16812 | 1.175 |
| 11:02 ET | 100 | 1.175 |
| 11:06 ET | 24087 | 1.17 |
| 11:08 ET | 200 | 1.175 |
| 11:11 ET | 100 | 1.175 |
| 11:13 ET | 664 | 1.175 |
| 11:15 ET | 100 | 1.17 |
| 11:18 ET | 1651 | 1.175 |
| 11:20 ET | 500 | 1.175 |
| 11:22 ET | 100 | 1.175 |
| 11:29 ET | 100 | 1.175 |
| 11:36 ET | 100 | 1.175 |
| 11:42 ET | 411 | 1.175 |
| 11:47 ET | 2354 | 1.1704 |
| 11:49 ET | 400 | 1.175 |
| 11:51 ET | 802 | 1.175 |
| 11:54 ET | 1024 | 1.175 |
| 12:00 ET | 100 | 1.175 |
| 12:02 ET | 200 | 1.1707 |
| 12:03 ET | 353 | 1.175 |
| 12:05 ET | 300 | 1.1775 |
| 12:07 ET | 681 | 1.175 |
| 12:09 ET | 200 | 1.175 |
| 12:12 ET | 710 | 1.175 |
| 12:14 ET | 200 | 1.18 |
| 12:18 ET | 100 | 1.175 |
| 12:21 ET | 300 | 1.175 |
| 12:25 ET | 100 | 1.175 |
| 12:30 ET | 303 | 1.175 |
| 12:34 ET | 200 | 1.175 |
| 12:41 ET | 100 | 1.175 |
| 12:43 ET | 264 | 1.175 |
| 12:45 ET | 6122 | 1.175 |
| 12:48 ET | 1065 | 1.175 |
| 12:50 ET | 988 | 1.17 |
| 12:52 ET | 100 | 1.175 |
| 12:54 ET | 300 | 1.175 |
| 12:59 ET | 100 | 1.18 |
| 01:01 ET | 583 | 1.172 |
| 01:03 ET | 400 | 1.18 |
| 01:08 ET | 565 | 1.1791 |
| 01:10 ET | 418 | 1.175 |
| 01:12 ET | 732 | 1.18 |
| 01:14 ET | 200 | 1.175 |
| 01:15 ET | 300 | 1.175 |
| 01:17 ET | 7945 | 1.175 |
| 01:19 ET | 4154 | 1.18 |
| 01:21 ET | 100 | 1.18 |
| 01:24 ET | 655 | 1.18 |
| 01:26 ET | 1000 | 1.175 |
| 01:28 ET | 504 | 1.175 |
| 01:30 ET | 205 | 1.18 |
| 01:33 ET | 2544 | 1.175 |
| 01:35 ET | 100 | 1.18 |
| 01:37 ET | 600 | 1.18 |
| 01:39 ET | 100 | 1.18 |
| 01:42 ET | 668 | 1.175 |
| 01:44 ET | 2290 | 1.18 |
| 01:46 ET | 300 | 1.18 |
| 01:48 ET | 200 | 1.18 |
| 01:50 ET | 534 | 1.175 |
| 01:51 ET | 2711 | 1.18 |
| 01:53 ET | 2958 | 1.19 |
| 01:55 ET | 2086 | 1.185 |
| 01:57 ET | 1990 | 1.19 |
| 02:00 ET | 222 | 1.18 |
| 02:02 ET | 20024 | 1.18 |
| 02:04 ET | 400 | 1.175 |
| 02:08 ET | 100 | 1.175 |
| 02:09 ET | 761 | 1.175 |
| 02:13 ET | 914 | 1.175 |
| 02:15 ET | 100 | 1.18 |
| 02:18 ET | 5689 | 1.17 |
| 02:20 ET | 716 | 1.175 |
| 02:22 ET | 300 | 1.175 |
| 02:24 ET | 1101 | 1.175 |
| 02:26 ET | 4787 | 1.17 |
| 02:27 ET | 200 | 1.17 |
| 02:29 ET | 349 | 1.17 |
| 02:31 ET | 300 | 1.175 |
| 02:33 ET | 300 | 1.17 |
| 02:36 ET | 496 | 1.175 |
| 02:40 ET | 1500 | 1.17 |
| 02:42 ET | 100 | 1.175 |
| 02:44 ET | 200 | 1.175 |
| 02:45 ET | 400 | 1.175 |
| 02:47 ET | 200 | 1.18 |
| 02:49 ET | 448 | 1.175 |
| 02:51 ET | 556 | 1.175 |
| 02:54 ET | 100 | 1.175 |
| 02:56 ET | 300 | 1.175 |
| 02:58 ET | 300 | 1.18 |
| 03:00 ET | 100 | 1.18 |
| 03:02 ET | 300 | 1.175 |
| 03:03 ET | 200 | 1.18 |
| 03:05 ET | 400 | 1.18 |
| 03:07 ET | 2200 | 1.18 |
| 03:09 ET | 800 | 1.18 |
| 03:12 ET | 400 | 1.175 |
| 03:14 ET | 400 | 1.18 |
| 03:16 ET | 100 | 1.18 |
| 03:18 ET | 900 | 1.175 |
| 03:20 ET | 400 | 1.18 |
| 03:21 ET | 400 | 1.17 |
| 03:23 ET | 500 | 1.18 |
| 03:25 ET | 600 | 1.18 |
| 03:27 ET | 430 | 1.18 |
| 03:30 ET | 34757 | 1.185 |
| 03:32 ET | 400 | 1.185 |
| 03:34 ET | 500 | 1.19 |
| 03:36 ET | 1700 | 1.19 |
| 03:38 ET | 15364 | 1.185 |
| 03:39 ET | 30856 | 1.2 |
| 03:41 ET | 1500 | 1.2 |
| 03:43 ET | 1500 | 1.195 |
| 03:45 ET | 600 | 1.195 |
| 03:48 ET | 3000 | 1.195 |
| 03:50 ET | 31450 | 1.19 |
| 03:52 ET | 3638 | 1.18 |
| 03:54 ET | 200 | 1.185 |
| 03:56 ET | 3100 | 1.19 |
| 03:57 ET | 7220 | 1.18 |
| 03:59 ET | 6732 | 1.19 |
May 7, 2024
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones*DJ Aclaris Therapeutics 1Q Loss/Shr 24c >ACRS, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
Apr 30, 2024
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update, from 7:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
Apr 23, 2024
Press Release: Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer, from 8:01AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:01AM ET on Tuesday Apr 23, 2024 by Dow JonesFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer, from 8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aclaris Therapeutics Inc | 84.8M | -1.1x | --- |
Enzo Biochem Inc | 55.8M | -2.3x | --- |
Elutia Inc | 80.6M | -1.4x | --- |
Prenetics Global Ltd | 70.9M | -1.3x | --- |
Aadi Bioscience Inc | 46.9M | -0.7x | --- |
Gritstone bio Inc | 85.5M | -0.5x | --- |
Company Information
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Contact Information
- Headquarters
- 701 Lee Road, Suite 103WAYNE, PA, United States 19087
- Phone
- 484-324-7933
- Fax
- 302-655-5049
Executives
- Non-Executive Chairman of the Board, President, Interim Chief Executive Officer, Co-Founder
- Neal Walker
- Chief Financial Officer
- Kevin Balthaser
- Chief Scientific Officer
- Joseph Monahan
- Chief Business Officer
- James Loerop
- Lead Independent Director
- Christopher Molineaux
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $84.8M |
|---|---|
Revenue (TTM) | $31.1M |
Shares Outstanding | 71.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.10 |
EPS | $-1.09 |
Book Value | $2.22 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -277.55% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
